Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Natalia Scaramellini, MD, Carola Arighi, MD, Alessia Marcon, MD, Dario Consonni, MD, Elena Cassinerio, MD, Giovanna Graziadei, MD, Maria Domenica Cappellini, MD, Irene Motta, MD

Blood (2019) 134 (Supplement_1): 3542.

https://doi.org/10.1182/blood-2019-130237

Published: 2019

Journal Articles

Retrospective Analysis of Compliance and Efficacy of a Novel Formulation of Deferasirox

Jamila Holloway, BS, Chisom Okezue, Jennifer Webb, MD

Blood (2018) 132 (Supplement 1): 5877.

https://doi.org/10.1182/blood-2018-99-118810

Published: 2018

Journal Articles

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Simon Cheesman, Raakhee Shah, MPharm, Sara Trompeter, MD, Perla Eleftheriou, FRCPath, MRCP, Bernadette Hylton, RN, Maciej W Garbowski, MDPhD, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 1062.

https://doi.org/10.1182/blood-2018-99-119030

Published: 2018

Journal Articles

Predicting Serum Ferritin Levels in Patients with Iron Overload Treated with the Film-Coated Tablet of Deferasirox during the Eclipse Study

Ali Taher, MDPhDFRCP, Sebastian Weber, Jackie Han, Andreas Bruederle, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2017) 130 (Supplement 1): 3508.

https://doi.org/10.1182/blood.V130.Suppl_1.3508.3508

Published: 2017

Journal Articles

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

Justin Keen, PhD, Dave Miller, PhD, Simon Tulloch, BA MA BM BCh

Blood (2017) 130 (Supplement 1): 2215.

https://doi.org/10.1182/blood.V130.Suppl_1.2215.2215

Published: 2017

Journal Articles

Deferasirox Adherence and Persistence Among Texas Medicaid Patients Taking Dispersible Tablets and Film-Coated Tablets

Kristin Richards, PhD, Kenneth A Lawson, PhD, Qayyim Said, PhD, Rahul Sasane, PhD

Blood (2017) 130 (Supplement 1): 4723.

https://doi.org/10.1182/blood.V130.Suppl_1.4723.4723

Published: 2017

Journal Articles

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

Norbert Gattermann, MD, Rosa Coll, MD, Lutz Jacobasch, Allameddine Allameddine, Laurie DeBonnett, Amin Azmon, Jie Jin

Blood (2017) 130 (Supplement 1): 2984.

https://doi.org/10.1182/blood.V130.Suppl_1.2984.2984

Published: 2017

Journal Articles

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Ali T. Taher, MD PhD, Raffaella Origa, Silverio Perrotta, Alexandra Kouraklis, Giovan Battista Ruffo, Antonis Kattamis, MD, Ai-Sim Goh, Annelore Cortoos, Vicky Huang, Marine Weill, Raquel Merino Herranz, John B. Porter, BA MB BChir MRCP(Path) FRCP(Path) MD

Blood (2016) 128 (22): 1285.

https://doi.org/10.1182/blood.V128.22.1285.1285

Published: 2016

Journal Articles

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Blood (2016) 128 (22): 850.

https://doi.org/10.1182/blood.V128.22.850.850

Published: 2016

Journal Articles

Iron Chelation Therapy: A Review of the Literature on the Issues and Importance of Adherence to Treatment in Iron Overload

Vicky Huang, Cecilia Luini, Ali El-Ali, Sophia Kessabi

Blood (2015) 126 (23): 4748.

https://doi.org/10.1182/blood.V126.23.4748.4748

Published: 2015

Journal Articles

Dasatinib Can Be Administered Orally with or without a Meal.

Sanjeev Kaul, PhD, Chiyuan Wu, PhD, Shelley Mayfield, CCRP, James Manning, PhD, Anne Blackwood-Chirchir, MD

Blood (2007) 110 (11): 4569.

https://doi.org/10.1182/blood.V110.11.4569.4569

Published: 2007

NARROW

Iron Chelation and Ferritin below 500 Mcg/L in Transfusion Dependent Thalassemia: Beyond the Limits of Clinical Trials

Retrospective Analysis of Compliance and Efficacy of a Novel Formulation of Deferasirox

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Predicting Serum Ferritin Levels in Patients with Iron Overload Treated with the Film-Coated Tablet of Deferasirox during the Eclipse Study

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

Deferasirox Adherence and Persistence Among Texas Medicaid Patients Taking Dispersible Tablets and Film-Coated Tablets

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

New Film-Coated Tablet Formulation of Deferasirox Is Well Tolerated in Patients with Thalassemia or MDS: Results of the Randomized, Phase II E.C.L.I.P.S.E. Study

Improved Patient-Reported Outcomes with a Film-Coated Versus Dispersible Tablet Formulation of Deferasirox: Results from the Randomized, Phase II E.C.L.I.P.S.E. Study

Iron Chelation Therapy: A Review of the Literature on the Issues and Importance of Adherence to Treatment in Iron Overload

Dasatinib Can Be Administered Orally with or without a Meal.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only